A semi-random mutagenesis approach was followed to increase the performance of penicillin acylase PAS2 in the kinetically controlled synthesis of ampicillin from 6-aminopenicillanic acid (6-APA) and activated D-phenylglycine derivatives. We directed changes in amino acid residues to positions close to the active site that are expected to affect the catalytic performance of penicillin acylase: α α α αR160, α α α αF161, and β β β βF24. From the resulting triple mutant gene bank, 6 improved PAS2 mutants were recovered by only screening 700 active mutants with a HPLC-based screening method. A detailed kinetic analysis of the three most promising mutants, T23, TM33, and TM38, is presented. These mutants allowed the accumulation of ampicillin at 4 to 5 times higher concentrations than the wild-type enzyme, using D-phenylglycine methyl ester as the acyl donor. At the same time, the loss of activated acyl donor due to the competitive hydrolytic side reactions could be reduced to less than 20 % with the mutant enzymes compared to > 80 % with wild-type PAS2. Although catalytic activity dropped by a factor 5 to 10, the enhanced synthetic performance of the recovered penicillin acylase variants makes them interesting biocatalysts for the production of β β β βlactam antibiotics.
INTRODUCTION
Already since several decades, penicillin acylase (penicillin amidase, PA, EC 3.5.1.11) is used for the hydrolytic release of 6-aminopenicillanic acid (6-APA) from fermentatively obtained natural penicillins, which is a central step in the production of semi-synthetic β-lactam antibiotics. Recently, also biocatalytic processes using this enzyme for the kinetically controlled condensation of activated acyl moieties with 6-APA or other β-lactam nuclei have been developed (Bruggink et al., 1998) . Although being competitive with traditional chemical synthesis routes, these enzymatic procedures suffer from the fact that the desired synthesis of β-lactam antibiotics is accompanied by two side reactions, leading to the loss of activated acyl donor and limiting the product yield: (1) hydrolysis of the activated acyl donor, and (2) hydrolysis of the formed antibiotic. Efforts to overcome this problem have mostly focused on a change in reaction conditions, such as pH optimization (Youshko et al., 2002b) , the use of supersaturated substrate solutions (Youshko et al., 2004) or immobilized enzyme preparations (Alvaro et al., 1990) and medium engineering (Fernández-Lafuente et al., 1996) . However, it was shown that the intrinsic kinetic properties of the employed biocatalyst also have a major impact on the efficiency of the synthetic reaction (Hernández-Jústiz et al., 1999; Youshko et al., 2002a; Alkema et al., 2003) .
During PA-catalyzed antibiotic synthesis, the formation of the synthetic product Ps, i.e. the antibiotic, as well as the formation of the hydrolytic byproduct Ph proceed via the formation of a covalent acyl-enzyme intermediate EAc, which is the ratelimiting step in the catalytic process (kinetic scheme: see Chapter 5, Fig. 4 ). EAc can then be attacked by one of two possible nucleophiles: either the β-lactam nucleus N, leading to the desired product Ps, or by a water molecule, which results in the formation of Ph. The ratio between the initial production rates of synthetic product (v Ps ) and hydrolytic product (v Ph ), and the maximal level of product accumulation that is obtained (Ps max ) depend on the initial substrate concentrations [N] 0 and [AD] 0 , and the kinetic parameters of the enzyme. In fact, antibiotic formation in PA-catalyzed reactions is sufficiently described by only three complex kinetic parameters, α, β 0 , and γ, according to Eq. 1 (Youshko et al., 2002a) : Here, 1/γ is the maximum that is reached for [N] → ∞, while β 0 constitutes the initial slope of a (v Ps /v Ph ) ini vs.
[N] plot. The third parameter, α, introduces the fact that the synthesized antibiotic is also a substrate for the enzyme, leading to its hydrolysis. Equation 3 Parameter α actually reflects the relative specificity of PA for the antibiotic with respect to the activated acyl donor and should be as small as possible to allow high product accumulation in a synthesis reaction. Parameters β 0 and 1/γ, in contrast, preferably should be high to prevent the formation of large amounts of hydrolytic byproduct. The use of a PA with favorable kinetic parameters for the synthesis of a specific antibiotic thus takes a key position in the design of an efficient production process. Biocatalysts with desired properties can be either obtained from nature, applying search strategies that range from traditional screening of culture collections to screening of metagenomic gene banks (Handelsman et al., 1998; Lorenz et al., 2002) , or by improving already available enzymes (Kazlauskas, 2000; Zhao et al., 2002) . Examples for the first approach are the PAs of Kluyvera citrophila, Bacillus megaterium, Proteus rettgeri, or Alcaligenes faecalis that were all detected for the first time by assaying pure bacterial cultures (Huber et al., 1972; Barbero et al., 1986) . Unfortunately, none of these enzymes seems to be better suited for synthetic purposes than the already known PA of E. coli (Hernández-Jústiz et al., 1999) . In contrast, an enzyme with better kinetic properties for 6-APA-derived antibiotic production, PAS2, was isolated from a soil metagenomic gene library (Chapter 4). PAS2 allows significantly improved antibiotic yields and, concomitantly, lower amounts of hydrolytic byproduct than the industrially employed E. coli PA (Chapter 5), with which it has 51.4 % of its amino acid residues in common.
In this study, we explored the possibility to further increase the synthetic performance of PAS2 for ampicillin production, using a semi-random mutagenesis procedure. By simultaneous randomization of three amino acid residues close to the active site, a gene library comprising 6,000 original mutants was created. Since the three selected residues are conserved in the E. coli PA and are known to greatly affect the kinetic properties of this enzyme, we anticipated that the mutants would show significant variations in catalytic behavior. Indeed, 6 clearly improved enzymes were found when screening only 700 active mutants. A detailed kinetic analysis of the three most promising PAS2-derivatives is presented.
MATERIALS AND METHODS

Chemicals
Ampicillin and cephalexin were purchased from Sigma. D-Phenylglycine (PG) was from Acros. 6-Aminopenicillanic acid (6-APA), 7-aminodesacetoxycephalosporanic acid (7-ADCA), D-phenylglycine methyl ester (PGM), and D-phenylglycine amide (PGA) were provided by DSM Life Sciences (Delft, The Netherlands). The colorimetric substrate 2-nitro-5-[(phenylacetyl)amino]-benzoic acid (NIPAB) was synthesized by reacting phenylacetic acid chloride with 5-amino-2-nitro-benzoic acid in a water/acetone mixture. D-phenylacetyl-L-leucine (PAL) was obtained through standard organic chemical peptide coupling chemistry. Care was taken that no free leucine was present in the prepared sample.
Plasmids and strains
For all plasmid constructs described in this study, E. coli TOP 10 [∆(ara-leu )7697, Invitrogen] was used as the host organism. pBADPAS2 is a 6.7 kb plasmid carrying the wild-type pas2 gene under the control of the pBAD promoter (Chapter 5). pPAS2CAT is a similar construct, just conferring chloramphenicol instead of ampicillin resistance to prevent interference of β-lactamase activity with β-lactam antibiotic synthesis experiments in whole cells. To obtain this construct, pBADPAS2 was cut with BspHI (New England Biolabs) to remove the β-lactamase gene. The remaining 5.7 kb fragment was isolated from gel with the QIAEX II gel extraction kit (Qiagen), blunted with Klenow polymerase (Invitrogen) and ligated to an also gelpurified blunt 1.2 kb fragment with T4 ligase (Invitrogen). The 1.2 kb fragment carried a chloramphenicol acetyltransferase gene (cat) and originated from the plasmid pEC (provided by DSM, Delft, The Netherlands), from which it was removed by BspHI/EcoRI restriction (New England Biolabs). All DNA manipulations were carried out according to the instructions of the manufacturers of the used materials. The construct was transformed to E. coli by electroporation and confirmed by restriction analysis. All media used to grow clones carrying the wild-type pPAS2CAT plasmid or mutant derivatives were supplied with 68 mg l -1 chloramphenicol.
Triple site-saturating mutagenesis
Two degenerate primers were designed, one for the random mutagenesis of amino acid residues αR160 and αF161 (5'gtg ggc act atg gcc aac nng/c nng/c tcg gac gcc aat agc gaa atc g 3'), and one for position βF24 (5'ggc ggg gtt cca cca gcc c/gnn ctg cgg gcc gtt taa cag 3'). For the easy identification of real mutants, primer αR160X/αF161X was set up to remove a unique NcoI restriction site and primer βF24X to introduce an additional MseI site, both leading to characteristic differences in the restriction patterns of wildtype and mutant plasmids (restriction sites underlined, mutations in bold). To reduce codon bias, the third position of each random codon was fixed to be a guanine or a cytosine. An outline of the used mutagenesis procedure is shown in Fig. 1 . In the first step, a 500-bp fragment containing all three randomized codons was PCR-amplified with the two degenerate primers described above. The reaction was carried out with Pfu Turbo polymerase (Stratagene) under standard conditions, using 50 ng pPAS2CAT as the template and 125 ng of each of the primers. The amplified fragment (megaprimer) was purified on gel with the QIAEX II gel extraction kit (Qiagen) and used as a forward and reverse primer set in a normal QuickChange site-directed mutagenesis procedure (Stratagene) according to the instructions of the manufacturer. After ethanol precipitation, the reaction mixture was resuspended in water and mutant plasmids were transformed to E. coli TOP10 by electroporation. Transformants were plated on LB agar (Sambrook et al., 1989) . Mutant strains obtained by this procedure usually carry two plasmid populations with different mutations, one originating from each of the different strands of the original (chimeric) mutant plasmid. To solve this problem, all colonies were washed from the agar plates and used for plasmid Figure 1 . Mutagenesis procedure used in this study. In the first step, a PCR product is prepared, using two degenerate primers that carry the desired randomized codons and the wild-type plasmid as the template. This product is then used as a megaprimer (3 randomized positions) in a standard QuickChange site-directed mutagenesis procedure (Stratagene) to yield the desired triple mutants.
preparation with the High Pure Plasmid Isolation Kit (Roche). The plasmid mix was then retransformed to E. coli to produce transformants, each carrying only one type of plasmid. The resulting amplified gene bank was then subjected to growth selection and screening. Interesting mutants were sequenced with at least 2-times coverage of each base by BaseClear Holding BV (Leiden, The Netherlands).
Selection of active mutants and screening for improved synthesis
Active mutants were selected by their ability to grow on phenylactyl-L-leucine as the sole source of leucine (Forney and Wong, 1989 ) in a minimal medium supplied with 0.2 % (w/v) glucose and 15 g l -1 agarose as described before (Chapter 4). PAL was added at a concentration of 10 mg l -1 and 0.2 % (w/v) arabinose were included in the medium to induce protein expression from P BAD . After 5 days of growth at 30°C, single colonies were transferred from the agar plates to 96-well microtiter plates (MTPs) filled with 200 µl liquid LB medium per well. After overnight incubation at 30°C and 200 rpm orbital shaking, 50 µl of 50 % glycerol were added per well and plates were stored as frozen stocks at -80°C.
For the first round of screening by high-performance liquid chromatography (HPLC), plates were defrosted and 20 µl aliquots of the stock cell suspensions were transferred to fresh MTPs and used to inoculate 180 µl of LB medium. MTPs were incubated at 17°C with orbital shaking at 200 rpm for 48 h before 50 µl of 10 % arabinose solution were added. After incubation for another 24 h at 17°C, cells were collected by centrifugation for 5 min at 2,500 rpm in a MSE Mistral 2000 MTP centrifuge. They were resuspended in 200 µl of substrate solution per well (15 mM PGA and 10 mM 6-APA in 50 mM potassium phosphate buffer, pH 7.0) and incubated at 30°C. After 24 h, 10 µl of the reaction mixtures were transferred to fresh MTPs and quenched by the addition of 90 µl HPLC eluens [340 mg l -1 sodium dodecylsulfate and 680 mg l -1 KH 2 PO 4 ·3H 2 O in a 30:70 (v/v) acetonitrile/water mixture of pH 3.0 (adjusted with diluted phosphoric acid)]. Liquid handling was done with a Plato 3001 automated pipetting station (Rosys AG, Switzerland) that also served as a 96-well MTP format autosampler for HPLC injection. HPLC analyses were carried out using a 3-cm Alltech Alltime C18 3u column in connection with Jasco PU-980 pumps and a Jasco MD-910 detector set at 214 nm. Compounds were isocratically eluted at a flow rate of 5 ml min -1 with HPLC eluens, which allowed the analysis of one sample in 3 min. The ratio of the areas of the product peaks, i.e. ampicillin and PG, in each chromatogram was determined and compared to the one of the E. coli (pPAS2CAT) control. Mutant strains exhibiting an at least 2-fold increased ampicillin/PG peak ratios or showing exceptionally high conversion rates were analyzed in more detail for their performance in the synthesis of ampicillin.
In this second round of HPLC screening, complete progress curves for the synthesis of ampicillin from 15 mM PGA and 25 mM 6-APA in 50 mM potassium phosphate buffer (pH 7.0) were recorded at 30°C, using periplasmatic extracts and enzyme concentrations of 5-10 µM. Extracts were prepared and analyzed for their content of active penicillin acylase as described in paragraph 2.5. A similar HPLC setup as for the robotic screening served for this analysis, however, based on a 10-cm Chrompack C18 column. Here, compounds were isocratically eluted at a flow rate of 1 ml min -1 . Peak areas were related to the concentration of the respective compounds by calibration curves that were established with solutions of the pure compounds.
Preparation of periplasmatic extracts and enzyme purification
Periplasmatic extracts were prepared at different scales. For the verification of whole cell screening results in the second round of HPLC screening, 5-ml cultures were used as a starting material, while 1-l cultures were used for protein purification. In both cases, clones containing the wild-type or mutant PAS2 gene were grown in LB at 17°C with rotary shaking at 200 rpm. After 2 days of growth, the medium was supplied with 0.8 % arabinose for the induction of protein expression. After another 24 h of incubation, cells were harvested by centrifugation at 5,000 g for 10 min (4°C). To prepare a periplasmatic extract, cells were resuspended in 1/10 of the original culture volume of ice-cold osmotic shock buffer (20 % sucrose, 100 mM Tris-HCl, 10 mM EDTA; pH 8.0) and centrifuged as described above. Cell walls were disrupted by resuspending the cell pellet in 1/50 of the original culture volume of ice-cold 1 mM EDTA and cell debris was removed by another centrifugation step.
Wild-type PAS2 and mutant enzymes were purified as described before (Chapter 5). The amount of active enzyme in penicillin acylase preparations was determined by titration with the irreversible inhibitor phenylmethylsulfonyl fluoride (PMSF). Enzyme preparations were incubated with different concentrations of PMSF in 50 mM potassium phosphate buffer (pH 7.0) at room temperature for 15 min. Residual activity was measured with NIPAB or ampicillin as a substrate. The release of 5-amino-2-nitrobenzoic acid from NIPAB was followed spectrophotometrically at 405 nm (∆ε 405nm = 9.09 mM -1 cm -1 ) with a Perkin Elmer Bio40 UV/VIS spectrometer, while hydrolysis of ampicillin was monitored by withdrawing samples from the reaction mixtures at different time points in the initial phase of conversion and analyzing them by HPLC (10-cm Chrompack C18 column).
Determination of kinetic parameters
All enzymatic conversions were carried out in 50 mM potassium phosphate buffer (pH 7.0) at 30°C. Steady-state kinetic parameters of the mutant enzymes for the hydrolysis of PGA, PGM, ampicillin, and cephalexin were determined by monitoring the initial velocities of substrate conversion at various substrate concentrations by HPLC (10-cm Chrompack C18 column). Product concentrations were determined at several times in order to obtain at least three data points in the initial phase of conversion. Steady-state parameters of PAS2 were determined as described before (Chapter 5).
Kinetically controlled enzymatic synthesis of ampicillin and cephalexin was carried out by mixing enzyme with solutions of activated acyl donor (PGA or PGM) and 6-APA or 7-ADCA, respectively. The initial concentration of acyl donor was 15 mM in all experiments, whereas the concentration of β-lactam acyl acceptor varied between 0.5 and 200 mM. All reactants were monitored in time by HPLC analysis (10cm Chrompack C18 column) and initial rates of formation of the antibiotic (v Ps ) and the hydrolyzed acyl donor (v Ph ) were determined.
RESULTS AND DISCUSSION
Structure-inspired semi-random mutagenesis
Penicillin acylase PAS2 (accession AY573298) and E. coli PA (accession AAA24324) share 51.4 % of their amino acid residues. This degree of sequence identity was sufficiently high to obtain a homology model of PAS2 based on the known 3-D structure of the E. coli enzyme (Duggleby et al., 1995) . The model provided by the Swiss-Model service (http://www.expasy.org/swissmod/SWISS-MODEL.html) did not reveal significant changes of the geometry of the active site, and the spatial orientation of several amino acid residues that were shown to significantly affect the catalytic behavior of E. coli PA (Alkema, 2002a) perfectly matched between the two proteins. This agreement as well as the conservation in a number of different other PAs, such as of Proteus rettgeri (accession A56681), Alcaligenes faecalis (accession AAD11517) or Kluyvera citrophila (A26528), prompted us to chose the three residues αR160, αF161, and βF24 of PAS2 (corresponding to positions α145, α146, and β24 in E. coli PA) as targets for mutagenesis. Alkema et al. (2000) showed that residues αR145 and αF146 have an important impact on the affinity of the E. coli enzyme for phenylacetylated substrates and the positioning of substrates towards the catalytic serine in the active site. Via an induced fit mechanism, they participate in the formation of the β-lactam binding site. When 6-APA or derived antibiotics are bound, both residues interact with the β-lactam moiety: αR145 with the negatively charged carboxylate group via two bridging water molecules, and αF146 by van der Waals interactions with the 2β-methyl group of the thiazolidine ring (Brannigan et al., 2000; Done et al., 1998) . The phenyl ring of the side-chain of αF146 also participates in the formation of the AD binding pocket by interacting with the phenyl ring of the acyl compound. On the other side of the binding pocket, another phenylalanine is located, βF24, which also shows hydrophobic interaction with the acyl donor (Alkema et al., 2002b) .
While the importance of the three residues in E. coli PA -and most likely also in PAS2 -is obvious, it is though difficult to predict what effect a specific mutation will have on the catalytic performance of the enzyme in a kinetically controlled synthesis reaction. This is due to the fact that both the activated acyl donor as well as the antibiotic can serve for the formation of the covalent acyl-enzyme intermediate (EAc) . Therefore, optimization of e.g. the enzyme acylation reaction in order to increase the reactivity with the acyl donor usually also results in improved hydrolysis of the formed antibiotic. Also engineering the enzyme with respect to improved deacylation by the βlactam nucleophile is not straightforward, since increased reactivity of N is often accompanied by an increased specificity also for the β-lactam antibiotic. In the end, only subtle changes in the geometry of the acyl-enzyme or the orientation and activation of the deacylating nucleophiles cause altered rates of product and byproduct formation and influence Ps max . These changes are mostly difficult to rationalize, which is particularly true for PAS2, of which an experimental 3-D structure is not yet available. Therefore, we chose to randomize the respective amino acid residues rather than to follow a completely rational approach. By simultaneously changing residues at three different sites, we were able to create a gene bank of high sequence diversity, while focusing on mutants that are likely to show significantly altered catalytic performance.
The procedure used to create the triple mutant bank of PAS2 is illustrated in Fig. 1 . Since two of the target positions for randomization concern adjacent amino acid residues, we only needed to design two degenerate primers: one for αR160 and αF161, and another for residue βF24. With these two primers, a (double-strand) megaprimer was prepared by simple PCR amplification that could subsequently be used in a standard QuickChange mutagenesis procedure. In this way, 6,000 original clones were created that were stored as an amplified gene library and screened for improved ampicillin synthesis.
Screening for higher ampicillin yields
The development of a direct screening method for increased antibiotic yields, e.g. by HPLC analysis, is difficult due to the temporary nature of product accumulation. After reaching a maximum (Ps max ), the product concentration decreases due to the enzymatically catalyzed hydrolysis of the antibiotic. Earlier experiments showed that an increase in (v Ps /v Ph ) ini at fixed reaction conditions is often coupled to an increase in Ps max and can therefore be used as an alternative screening criterion. This is in agreement with Eq. 1, which shows that an increase in β 0 and/or 1/γ (reflected by an increased rate ratio of synthetic and hydrolytic product formation) results in a higher Ps max if α remains unchanged or is even decreased. A problematic feature of this screening approach is the fact that improved mutants with respect to Ps max might be missed if they possess a superior α parameter, but have a similar (v Ps /v Ph ) ini as the wildtype enzyme. In the same way, mutants might seem improved upon screening, while actually not yielding more product if they have an unfavorably high α, which causes preference for the product over the activated acyl donor during enzyme acylation. Despite these limitations, we chose to use a screening procedure based on the described principle because of its relatively high throughput capacity, and refine the search by a second, more detailed round of analysis.
In the first round of HPLC screening, cell suspensions of mutant clones were analyzed in MTPs for the produced amount of Ps (ampicillin) and Ph (Dphenylglycine, PG) from D-phenylglycine amide (PGA) and 6-APA at a certain time. PGA was used as the acyl donor due to its high chemical stability and, consequently, low background hydrolysis under the applied reaction conditions. The peak ratio of ampicillin/PG formed after 24 h was compared to the one of a wild-type PAS2 culture. Since we could not assume all reaction mixtures to be in the initial phase of conversion, and the peak ratio changes in the course of reaction, several wild-type cultures with different induction levels were prepared in order to obtain a set of chromatograms with varying degrees of conversion. Each mutant chromatogram was then compared to the wild-type profile that showed the most similar conversion level. With this method, one 96-well MTP could be analyzed in about 5 h, leading to a throughput of maximally 4 plates per day. In order to decrease the number of clones that needs to be screened, clones expressing an active PAS2 variant were preselected on agar plates containing D-phenylacetyl-L-leucine (PAL) as the only source of leucine. Since only 20 % of all mutants were found to be active, the screening effort for synthetic activity was reduced by a factor 5 by only analyzing mutants that could grow on PAL medium. A total of 700 of these clones was subjected to a first round of HPLC screening (Fig. 2) .
Figure 2.
Screening for improved PAS2 mutants by HPLC with whole cells. Clones represented by filled dots were inspected in more detail in a second round of HPLC screening with periplasmatic extracts. Truly improved mutants that were subjected to further analysis are indicated by surrounding circles.
In preliminary experiments, we had compared the recovery of active clones by this growth selection method with the detection of activity in MTPs due to the hydrolysis of 2-nitro-5-[(phenylacetyl)amino]-benzoic acid (NIPAB), which is a well-known colorimetric substrate for penicillin acylases (Kutzbach and Rauenbusch, 1974) . While all clones able to hydrolyze NIPAB were also found to grow on PAL, about 15 % of the clones utilizing PAL could not hydrolyze NIPAB, which made us decide to use PAL for the recovery of active clones. Interestingly, the 6 truly improved mutants isolated in this study (see below) could not hydrolyze NIPAB or only at extremely low rates, which would have compromised their isolation if a prescreening on NIPAB had been included.
Besides selection on PAL plates, we also isolated transformants that could grow on medium supplied with amides such as D-phenylglycine amide, α-methylphenylglycine, or D-mandelamide (racemic mixture) as the only source of nitrogen. However, none of the 500 mutants selected on these media did show promising ampicillin/PG peak ratios or high activity when tested for ampicillin synthesis. From the PAL preselection, in contrast, 50 clones exhibited enhanced synthetic behavior. The recovery of improved mutants from PAL plates but not from nitrogen-limited media can be attributed to the fact that only traces of leucine need to be released by hydrolysis to sustain growth, while local concentrations of nitrogen are required to be in the µM-range for the formation of reasonably sized colonies. Mutants that show improved synthetic performance, but reduced hydrolytic activity may consequently not be able to grow on nitrogen-limited media. The 50 improved mutants from the PAL preselection were tested in more detail in a second round of HPLC analysis. Here, complete progress curves for the kinetically controlled synthesis of ampicillin from PGA and 6-APA were recorded to reveal whether the respective mutant indeed allowed higher maximal product accumulation than the wild-type. Six of the mutants showed significantly improved synthetic performance and were subsequently also tested with another common β-lactam nucleophile, 7-ADCA, in the synthesis of cephalexin. Dependence on the type of acyl donor was revealed by using either PGA or the methyl ester derivative of Dphenylglycine, PGM, as the acyl moiety. Improvements were most pronounced for the synthesis of ampicillin for all mutants, particularly with PGM that allowed up to 4 times higher product accumulation than obtained with the wild-type enzyme. In general, the 6 mutants showed similar trends in the test reactions. Progress curves of triple mutant TM23 are shown as examples in Fig. 3 . In contrast to the correspondence in synthetic behavior, the mutants were found to differ with respect to their amino acid residue substitutions (Table 1) . Remarkably, TM33 only comprised one amino acid residue change, βF24A, corresponding to the βF24A E. coli PA single mutant that was reported to allow high antibiotic yields (Alkema et al., 2002b) . However, improvements for the E. coli mutant were most pronounced in the synthesis of cephalexin, while TM33 performed best in the production of ampicillin, in both cases using PGM as the acyl donor. Although TM33 did not carry mutations at the other two sites, it was confirmed as a true triple mutant by restriction analysis and the presence of altered codons for residues αR160 and αF161. The other 5 mutants contained amino acid substitutions at all three target positions. While some mutations, i.e. αR180K and αF181L, have earlier been found to influence antibiotic synthesis in E. coli PA single mutants (Alkema et al., 2002b; Alkema et al., 2002c) , the effects of most substitutions and their combination have not been studied.
Kinetic characterization of the best mutants
While antibiotic yields were clearly improved for all mutants with PGA as the acyl donor (120 to 260 %), synthesis rates were strongly decreased, being less than 1 % of the wild-type rates. Activities with PGM were much higher for all mutants, but mutants TM26, TM42, and TM48 still maximally reached 3.6 % of the PAS2 synthesis rates. For a detailed kinetic characterization, we therefore focused on the three other mutants, TM23, TM33 and TM38 that exhibited 10 to 20 % of the wild-type activity in antibiotic formation. All experiments were carried out with purified enzyme preparations.
The steady-state parameters for the hydrolysis of the acyl donors used in this study as well as of the synthesized antibiotics are summarized in Table 2 . In agreement with the low conversion rates observed in the synthesis experiments, the k cat of all mutants for the tested acyl donors was decreased. TM23, TM33 and TM38 showed clear preference for hydrolysis of the ester compared to the amide substrate. Surprisingly, the wild-type enzyme was slightly more specific for the amide AD, although enzymecatalyzed ester hydrolysis is generally expected to be faster due to the comparatively lower chemical stability of the ester bond (Polgar, 1989) . Although several hypotheses exist that, for example, relate this unexpected feature to a distortion of the normally planar amide bond towards a structure that more resembles the tetrahedral transition state that leads to the formation of the covalent acyl-enzyme intermediate (Hedstrom et al., 1992; James et al., 1980; Polgar, 1989) , no structural evidence for the presence of the proposed mechanisms in PA has yet been provided. The increase in relative esterase/amidase activity of the mutants was also reflected in their α parameters for the synthesis of both ampicillin and cephalexin, which were much lower with PGM as the acyl donor than with PGA (Table 3) . While with PGM, α of all mutants was smaller than the one of the wild-type enzyme, partly explaining the high antibiotic yields, α was up to 17-fold higher for the amide acyl donor. This seems to be in contradiction to the observed increase in antibiotic accumulation with PGA as the substrate. However, not only the competition between antibiotic and activated acyl donor for acylation of the enzyme determines Ps max , but also the competition between the β-lactam nucleophile N and water for deacylation of the covalent acyl-enzyme intermediate (EAc), which is described by the parameters β 0 and 1/γ. With 10 to 40fold increases in β 0 and even up to 60 times higher values for 1/γ (Table 3) , improvements with respect to deacylation of EAc by the tested β-lactam compounds were large enough to compensate for the relative decrease of specificity for PGA compared to the antibiotic and allowed higher yields than with the wild-type enzyme.
Since formation of both reaction products, Ps and Ph, occurs via the same covalent intermediate (EAc), β 0 and 1/γ should be independent of the type of AD used, which is in agreement with our experimental results. Whereas for PAS2, (v Ps /v Ph ) ini could be determined for a whole range of concentrations of the β-lactam nucleophile (1 to 200 mM), allowing the experimental determination of both β 0 and 1/γ (Chapter 5), only β 0 could be measured for the three mutants. This is due to the fact that the synthetic reaction was so much preferred with these enzymes that already at relatively low nucleophile concentrations the amount of hydrolytic product was below the detection limit in the initial phase of conversion. Therefore, only β 0 could be measured at 6-APA and 7-ADCA concentrations below 5 mM, whereas 1/γ needed to be obtained by fitting [Ps] vs.
[Ph] plots that were derived from progress curves (Fig. 3) with Eq. 1, using the experimental values of α and β 0 . Good agreement was observed between the data derived from curves based on the use of the amide and the ester acyl donor (Fig. 4) , supporting the assumption that the formation of the acyl-enzyme intermediate is the rate-limiting step of the conversion. Interestingly, when 6-APA was used as the β-lactam nucleophile, improvements were more pronounced for 1/γ than for β 0 , whereas with 7-ADCA the opposite situation occurred. For mutants TM33 and 38, virtually no increase in 1/γ was observed in the synthesis of cephalexin. The high values of (v Ps /v Ph ) ini at low concentrations of 7-ADCA indicate that the affinity for this β-lactam nucleophile became higher due to the mutations in the substrate binding pocket, while the exclusion of water from the active site at high 7-ADCA concentrations was obviously not improved. In contrast, binding of 6-APA in the active site seemed to widely suppress the nucleophilic attack of water on the acyl-enzyme intermediate. 
Antibiotic yields at high substrate concentrations
Besides by α, β 0 , and γ, the maximal product yield of a given reaction is also determined by the initial substrate concentrations [N] 0 and [AD] 0 . To evaluate the performance of TM23, TM33, and TM38, we therefore modeled the maximal antibiotic accumulation (Eq. 1) for a range of substrate concentrations, using the parameters given in Table 3 . From Fig. 5 , it becomes apparent that all three mutants have a higher potential for the synthesis of antibiotics derived from 6-APA, particularly ampicillin, than from 7-ADCA. Although somewhat higher yields of cephalexin are predicted for low concentrations of 7-ADCA with PGA as the acyl donor, which is in agreement with our experiments (Fig. 3) , wild-type PAS2 allows significantly higher yields at nucleophile concentrations above 50 mM with about 100-fold higher conversion rates. When PGM and 6-APA are used, the drawback of lower activity (10-20 % of wildtype) may though become unimportant in view of the 4 to 5 times higher ampicillin concentrations that can be reached over the whole range of substrate concentrations. This is particularly interesting since the reaction can be accelerated just by adding more enzyme, while the maximal level of product accumulation that is reached in a kinetically controlled synthesis reaction can only be increased by using a better enzyme. The unproductive loss of activated acyl donor is also drastically reduced when using the mutant enzymes: at 200 mM 6-APA concentration, about 80 % of PGM is converted to ampicillin with the mutant enzymes, while only 17 % is used for synthesis with the wild-type PAS2 penicillin acylase, the remainder being hydrolyzed to Dphenylglycine (Fig. 5 ). In conclusion, our study demonstrates that focusing random mutagenesis to amino acid residues that are expected to affect the catalytic behavior of the target enzyme based on sequence and structural information is an efficient tool for rising the frequency of biocatalysts with a desired property in a mutant library. With this method, three mutant penicillin acylases carrying different amino acid substitutions were recovered that allow significantly higher ampicillin yields with PGM than the wildtype enzyme, while retaining relatively high catalytic activity.
Figure 5.
Maximal accumulation of ampicillin and cephalexin in PA-catalyzed, kinetically controlled conversions, using different substrate concentrations. Data were simulated with Eq. 1, using the complex kinetic parameters α, β 0 and γ given in Table 3. PAS2; TM23; TM33; and TM38. 
